North America was the largest of QuidelOrtho Corp’s 5 reported lines in fiscal 2025, at $1.49B — 55% of $2.73B.
| Segment | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| North America | $1.50B | $1.88B | $1.62B | $1.49B | |
| China | $58.00M | $310.10M | $325.00M | $334.70M | |
| Jpac | — | $272.70M | $279.40M | $293.00M | |
| Emea | $69.60M | $327.30M | $335.80M | $360.70M | |
| Latin America | — | $210.60M | $222.90M | $252.90M | |
| Other | $70.80M | — | — | — | |
| Total | $1.70B | $3.00B | $2.78B | $2.73B |
In fiscal 2025, which ended December 28, 2025, the 5 segments QuidelOrtho Corp reported in this breakdown added up to $2.73B. That was down 1.9% from $2.78B in fiscal 2024. North America was the largest segment, at $1.49B or 54.5% of the total, followed by Emea ($360.70M, 13.2%) and China ($334.70M, 12.3%). Together, the two largest segments made up 67.7% of this total.
Compared with fiscal 2024, Latin America grew the fastest, rising 13.5% to $252.90M. North America fell the most, down 8.1% to $1.49B.
Jpac (fiscal 2023) and Latin America (fiscal 2023) were first reported as separate segments during this period. The table also keeps 1 segment that QuidelOrtho Corp no longer reports, so earlier years can still be read on their original basis; use "Show 1 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2021 to 2025, as reported in QuidelOrtho Corp's annual filings.
Labs was the largest of QuidelOrtho Corp’s 5 reported lines in fiscal 2025, at $1.51B — 55% of $2.73B.
| Business Unit | FY 2021 | FY 2022 | FY 2023 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Point Of Care | $1.45B | $1.96B | $892.40M | $694.60M | $601.60M | |
| Labs | $44.80M | $820.20M | $1.43B | $1.43B | $1.51B | |
| Immunohematology | — | $296.80M | $512.00M | $522.00M | $543.80M | |
| Molecular Diagnostics | $200.50M | $96.70M | $31.70M | $24.00M | $26.50M | |
| Donor Screening | — | $97.00M | $135.90M | $115.10M | $52.60M | |
| Total | $1.70B | $3.27B | $3.00B | $2.78B | $2.73B |
In fiscal 2025, which ended December 28, 2025, the 5 revenue lines QuidelOrtho Corp reported in this breakdown added up to $2.73B. That was down 1.9% from $2.78B in fiscal 2024. Labs was the largest revenue line, at $1.51B or 55.1% of the total, followed by Point Of Care ($601.60M, 22.0%) and Immunohematology ($543.80M, 19.9%). Together, the two largest revenue lines made up 77.2% of this total.
Compared with fiscal 2024, Labs grew the fastest, rising 5.5% to $1.51B. Point Of Care fell the most, down 13.4% to $601.60M.
Immunohematology (fiscal 2023) and Donor Screening (fiscal 2023) were first reported as separate revenue lines during this period. This breakdown covers 6 fiscal years between 2021 and 2025, as reported in QuidelOrtho Corp's annual filings.
Domestic was the largest of QuidelOrtho Corp’s 2 reported lines in fiscal 2025, at $1.44B — 53% of $2.73B.
| Geography | FY 2023 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Domestic | $2.45B | $1.83B | $1.57B | $1.44B |
| Foreign | $814.30M | $1.17B | $1.21B | $1.29B |
| Total | $3.27B | $3.00B | $2.78B | $2.73B |
In fiscal 2025, which ended December 28, 2025, the 2 regions QuidelOrtho Corp reported in this breakdown added up to $2.73B. That was down 1.9% from $2.78B in fiscal 2024. Domestic was the largest region, at $1.44B or 52.6% of the total, followed by Foreign ($1.29B, 47.4%).
Compared with fiscal 2024, Foreign grew the fastest, rising 6.5% to $1.29B. Domestic fell the most, down 8.4% to $1.44B. Over fiscal 2023 to 2025, revenue across these regions went from $3.27B to $2.73B, a compound annual decline of 8.6%. Domestic's share of the total fell from 75.1% to 52.6% over the same years.
This breakdown covers 4 fiscal years between 2023 and 2025, as reported in QuidelOrtho Corp's annual filings.
QuidelOrtho Corp (QDEL) breaks its revenue down by segment, revenue line and region. In fiscal 2025, its largest segment was North America, with $1.49B or 54.5% of the total, followed by Emea at $360.70M (13.2%).
North America was QuidelOrtho Corp's largest segment in fiscal 2025, with $1.49B in revenue, 54.5% of the $2.73B reported across its 5 segments.
Labs was QuidelOrtho Corp's largest revenue line in fiscal 2025, with $1.51B in revenue, 55.1% of the $2.73B reported across its 5 revenue lines.
Domestic was QuidelOrtho Corp's largest region in fiscal 2025, with $1.44B in revenue, 52.6% of the $2.73B reported across its 2 regions.
Of the QuidelOrtho Corp segments reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Latin America grew the fastest, rising 13.5% from $222.90M to $252.90M.
Every figure is taken from QuidelOrtho Corp's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by segment covers fiscal 2021 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.